Last checked at 14 May 2021 09:30
Polarean Imaging plc
("Polarean" or the "Company")
Scientific presentations on hyperpolarised Xenon-129 at upcoming medical conferences
Polarean's investigational drug/device combination product to be prominently featured in presentations across a wide range of lung diseases
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational drug-device combination product to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces a number of abstracts and oral presentations highlighting the use of hyperpolarised Xenon-129 ("129Xe") will be made by leading academic researchers at the upcoming American Thoracic Society ("ATS 2021") virtual conference from 14-19 May 2021 and the International Society for Magnetic Resonance in Medicine ("ISMRM 2021") virtual conference from 15-20 May 2021.
23 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ATS 2021, consisting of 8 oral presentations and 15 e-poster presentations. Polarean is also supporting ATS 2021 by hosting a virtual exhibit booth.
Additionally, 34 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ISMRM 2021, consisting of 7 oral presentations and 27 e-poster presentations. Hyperpolarised 129Xe will also be discussed in a symposium on 17 May and in a sunrise session on 18 May. Furthermore, Polarean is supporting ISMRM 2021 by hosting a virtual exhibit booth.
Richard Hullihen, Chief Executive Officer of Polarean commented: "We are pleased at the important work being done by leading investigators in the field of functional lung imaging. The data being presented at these key scientific meetings will further add to the body of evidence on hyperpolarised 129Xenon, highlighting several areas of unmet needs in current diagnostic modalities. Research of 129Xe MRI in interstitial lung disease, long-COVID-19, asthma, COPD and interventional pulmonology procedures are among the presentations that will be showcased."
A subset of the abstracts that will be presented during the ATS 2021 and ISMRM conferences are listed below.
Lead Author and ATS Abstract Title | Presentation Date | Abstract Number | ATS Notes |
Mummy D et al.Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated with Improved Gas Exchange on Xenon-129 MRI | 16-May | 1052 | ORAL PRESENTATIONSession A12: Sunday, May 16, 2021 (3:30-5pm) |
Mcintosh M et al.Response to Benralizumab in Severe Asthma: Oscillometry and MRI Ventilation Defect Improvements in Participants with Abnormal FeNO | 18-May | 1111 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
Eddy RL et al.Structure-Function Imaging Phenotypes of Asthma Using CT and 129Xe MRI | 18-May | 1112 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
HE M et al.Probing Early-Stage Pulmonary Pathophysiology in Young Healthy E-cigarettes Users Using Hyperpolarized 129Xe MRI | 18-May | 1113 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
Bdaiwi, AS et al.In Vivo Lung Morphometry of Lymphangioleiomyomatosis Using Hyperpolarized 129Xe Diffusion MRI | 18-May | 1114 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
Bier E et al.Hyperpolarized 129Xe Magnetic Resonance Oscillation Imaging in Pulmonary Hypertension | 18-May | 1115 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
Mummy D et al.Hyperpolarized 129Xe MRI Features Identify Functional Differences That Do Not Correlate with Chest CT in Patients with Idiopathic Pulmonary Fibrosis | 18-May | 1116 | ORAL PRESENTATIONSession C4: Tuesday, May 18, 2021 (8-9:30am) |
Plummer JW et al.129Xe gas-exchange MRI to detect diffusion abnormalities in children following bone-marrow transplantation | 18-May | 1166 | ORAL PRESENTATIONSession C15: Tuesday, May 18, 2021 (3:30-5pm) |
Ruppert K et al.First Experience with Hyperpolarized 129Xe Imaging in a Recovered COVID-19 Patient | May 14-19 | 1998 | E-posterSession TP031
|
Ranota TK et al.The Use of Hyper-polarized 129Xe Pulmonary MRI for Study of the Lung Damage in COVID-19 Survivors, Preliminary Results | May 14-19 | 3835 | E-posterSession TP92 |
Matheson AM et al.This Is What COVID-19 Survival Looks Like: 129Xe MRI, Oscillometry and Pulmonary Function Measurements | May 14-19 | 4453 | E-posterSession TP117 |
Kooner HK et al.CT Mucus Score Predicts Benralizumab Response in Severe Asthma | May 14-19 | 4531 | E-posterSession TP120 |
Woodward E et al.Four Years Observation of the Emphysema Progression in Alpha-1 Antitrypsin Deficiency Using 3He/129Xe MRI | May 14-19 | 4574 | E-posterSession TP121 |
Hamedani H et al.Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized (HP) Xenon Lung Function Assessment | May 14-19 | 4578 | E-posterSession TP121 |
Bier E et al.Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy | May 14-19 | 4589 | E-posterSession TP122 |
Amzajerdian F et al.Exploring the Use of Continuous RF Irradiation for Xenon Polarization Transfer Contrast Imaging | May 14-19 | 4590 | E-posterSession TP122 |
Lead Author and ISMRM Abstract Title | Presentation Date | Abstract Number | ISMRM Notes |
Leewiwatwong S et al.Deep learning-based thoracic cavity segmentation for hyperpolarized 129Xe MRI | 18-May | 391 | ORAL PRESENTATION(Session: Machine Learning for Image Analysis) |
Mummy D et al.Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated With Improved Gas Exchange on Xenon-129 MRI | 19-May | 589 | ORAL PRESENTATION(Session: Lung) |
Hahn A et al.Response of Hyperpolarized 129Xe MRI measures of ventilation and gas-exchange to anti-fibrotic treatment in Idiopathic Pulmonary Fibrosis | 19-May | 591 | ORAL PRESENTATION(Session: Lung) |
Hamedani H et al.Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized Xenon Lung Function Assessment | 19-May | 592 | ORAL PRESENTATION(Session: Lung) |
Marshall H et al.Hyperpolarised xenon ventilation MRI in difficult asthma; initial experience in a clinical setting | 20-May | 680 | ORAL PRESENTATION(Session: Latest Advances in Hyperpolarized MRI) |
Bier E et al.Extension of a Diagnostic Model for Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy | 20-May | 681 | ORAL PRESENTATION(Session: Latest Advances in Hyperpolarized MRI) |
Albert B J et al.Preclinical Hyperpolarized 129Xe Ventilation Imaging Using 3D Spiral (FLORET) Encoding | 20-May | 684 | ORAL PRESENTATION(Session: Latest Advances in Hyperpolarized MRI) |
Rao M.Imaging Beyond Perfusion Using 129Xe MRI | 17-May | MEMBER-INITIATED SYMPOSIUM(Imaging Beyond Perfusion Using 129Xe MRI) | |
Woodward E et al.The Use of the 3He/129Xe MRI Lung Morphometry for a Longitudinal Observation of the Emphysema Progression in AATD Patients | 17-May | 1269 | E-poster(Session: Novel Contrast Mechanisms) |
Grist J et al.Utilizing hyperpolarised xenon MRI to detect gas transport deficiencies in post-COVID lungs | 17-May | 1736 | E-poster(Session: MRI in COVID-19) |
Ranota T et al.Feasibility of Single Breath-hold Isotropic Voxel 129Xe MRI in COVID-19 Survivors using a Key-Hole Method | 17-May | 1739 | E-poster(Session: Role of Advanced Imaging in COVID-19) |
Collier G et al.Imaging lung structure and function in acute COVID-19 patients with 129Xe and 1H MRI | 17-May | 1746 | E-poster(Session: Role of Advanced Imaging in COVID-19) |
Wild J.Hyperpolarized 129Xe MRI of the Lung | 18-May | SUNRISE SESSION(Lung MRI: You Can Do It!) | |
Lu T et al.Convolutional Neural Networks for Super-resolution of Hyperpolarized 129Xe MR Images of the Lung | 18-May | 1968 | E-poster(Session: Machine Learning to Reconstruct Accelerated Scans) |
Gandhi D B et al.Comparison of Respiratory-Gating Weighting Algorithms in Neonatal Pulmonary UTE-MRI | 18-May | 2273 | E-poster(Session: Pediatrics: Body Topics) |
Chan H-F et al.Comparison of UTE 1H lung MRI with quantitative CT and hyperpolarized 129Xe diffusion-weighted MRI in IPF | 19-May | 3214 | E-poster(Session: Lung: Disease Assessment) |
Eaden J et al.Correlation of global and regional hyperpolarised 129-Xenon MRI with quantitative CT in patients with idiopathic pulmonary fibrosis | 19-May | 3216 | E-poster(Session: Lung Disease Assessment) |
Bdaiwi A S et al.Optimizing Acquisition and Analysis for Diffusion Weighted Hyperpolarized 129Xe MRI of Pediatric and Adult Lungs | 20-May | 3558 | E-poster(Session: Hyperpolarization: Gas) |
Astley J et al.Comparison of 3D convolutional neural networks and loss functions for ventilated lung segmentation using multi-nuclear hyperpolarized gas MRI | 20-May | 3560 | E-poster(Session: Hyperpolarization: Gas) |
Schulte R et al.Imaging Gas-Exchange Lung Function using Density-Weighted MRSI and Hyperpolarised 129Xe Gas | 20-May | 3562 | E-poster(Session: Hyperpolarization: Gas) |
Pratt R et al.A 129Xe/1H Switched Frequency High Pass Birdcage Coil for Hyperpolarized 129Xe Gas Lung Imaging in Neonates at 1.5 T | 20-May | 3563 | E-poster(Session: Hyperpolarization: Gas) |
Norquay G et al.Temporal correlation of alveolar-capillary 129Xe signal dynamics with the cardiac cycle | 20-May | 3564 | E-poster(Session: Hyperpolarization: Gas) |
Amzajerdian F et al.Feasibility of Xenon Polarization Transfer Contrast Imaging using Continuous RF Irradiation | 20-May | 3565 | E-poster(Session: Hyperpolarization: Gas) |
Hamedani H et al.Reproducibility Study Measuring Ventilation, Gas Exchange and Surface-to-Volume Using Hyperpolarized Xenon in Free-breathing Human Subjects | 20-May | 3566 | E-poster(Session: Hyperpolarization: Gas) |
Rao M et al.3D isotropic spectroscopic imaging of hyperpolarized 129Xe in the human brain | 20-May | 3567 | E-poster(Session: Hyperpolarization: Gas) |
Chan H-F et al.Background field inhomogeneity effects on hyperpolarized 129Xe diffusion-weighted MRI at 1.5T and 3T | 20-May | 3568 | E-poster(Session: Hyperpolarization: Gas) |
Ruppert K et al.Detection of pulmonary abnormalities in a rabbit thoracic insufficiency syndrome model using hyperpolarized xenon-129 MRI | 20-May | 3569 | E-poster(Session: Hyperpolarization: Gas) |
Ball G et al.Modelling realistic Rb density and temperature distributions in a high throughput xenon-129 polariser | 20-May | 3570 | E-poster(Session: Hyperpolarization: Gas) |
Lu J et al.Template-based bias field correction of Hyperpolarized 129Xe Gas Ventilation MRI | 20-May | 3571 | E-poster(Session: Hyperpolarization: Gas) |
Bdaiwi A S et al.2D and 3D Spiral for Diffusion Weighted MRI with Hyperpolarized 129Xe | 20-May | 3575 | E-poster(Session: Hyperpolarization: Gas) |
Driehuys B et al.Establishing the Structurally Limited Healthy RBC to Barrier Ratio for 129Xe Gas Exchange MRI | 20-May | 3791 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Bier E et al.Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy | 20-May | 3792 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Doganay O et al.Assessment of Gas Exchange Parameters in Healthy and COPD Subjects using Hyperpolarized Xenon-129 MRI and Alveolar Gas-exchange Model | 20-May | 3793 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Loza L et al.A Comparison of Multi-breath Wash-in/Wash-out and RF-Contrast Hyperpolarized 129Xe Imaging Schemes for Quantifying Fractional Ventilation | 20-May | 3794 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Costa M L et al.Optimized Magnetization Decay Correction of Hyperpolarized Xe Ventilation Images Using Radial-Keyhole | 20-May | 3795 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Qian Y et al.Simulating the impact of asymmetric geometries on apparent alveolar septal wall thickness measurements with hyperpolarized xenon-129 MRI | 20-May | 3796 | E-poster(Session: Hyperpolarization: Gas & Non-Gas) |
Enquiries:
Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
Richard Hullihen, Chief Executive Officer | Via Walbrook PR | |||
Jonathan Allis, Chairman | ||||
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) | ||||
Nick Adams / Fred Walsh (Corporate Broking) | ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 | |||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.